Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two pharmaceutical drugs, bethanechol and omeprazole. Bethanechol is a cholinergic agonist that stimulates muscarinic receptors, primarily used to treat urinary retention by increasing bladder muscle tone and promoting urination. It may also be used for certain gastrointestinal conditions such as gastroparesis or postoperative ileus due to its prokinetic effects[3][4][5]. Omeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, commonly indicated for gastroesophageal reflux disease (GERD), peptic ulcer disease, and other acid-related disorders[6]. There are no known fixed-dose combination products containing both drugs; this entry refers to their concurrent use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bethanecol + omeprazole.